WO2000077003A1 - Composes de pyrrolopyridazine optiquement actifs - Google Patents
Composes de pyrrolopyridazine optiquement actifs Download PDFInfo
- Publication number
- WO2000077003A1 WO2000077003A1 PCT/JP2000/003895 JP0003895W WO0077003A1 WO 2000077003 A1 WO2000077003 A1 WO 2000077003A1 JP 0003895 W JP0003895 W JP 0003895W WO 0077003 A1 WO0077003 A1 WO 0077003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- optically active
- acceptable salt
- pyro
- Prior art date
Links
- YTJAMOLQXDNLJC-UHFFFAOYSA-N N1N=CC=C2N=CC=C21 Chemical class N1N=CC=C2N=CC=C21 YTJAMOLQXDNLJC-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 18
- 208000025865 Ulcer Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- -1 pyridazine compound Chemical class 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 239000000460 chlorine Substances 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- 239000011737 fluorine Substances 0.000 claims description 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 9
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 150000004892 pyridazines Chemical class 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- FPETYBYJNAIDIQ-UHFFFAOYSA-N [difluoro(methoxy)methyl] hypofluorite Chemical compound COC(F)(F)OF FPETYBYJNAIDIQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 abstract description 14
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 210000004211 gastric acid Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000001681 protective effect Effects 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 125000000217 alkyl group Chemical group 0.000 abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 210000003097 mucus Anatomy 0.000 abstract 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 35
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000027119 gastric acid secretion Effects 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000012442 inert solvent Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940117389 dichlorobenzene Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 108030003004 Triphosphatases Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- FHADSMKORVFYOS-UHFFFAOYSA-N cyclooctanol Chemical compound OC1CCCCCCC1 FHADSMKORVFYOS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XLZCIXFPTHCUFB-UHFFFAOYSA-N dmf pocl3 Chemical compound CN(C)C=O.ClP(Cl)(Cl)=O XLZCIXFPTHCUFB-UHFFFAOYSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 1
- QVCUKHQDEZNNOC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.2]octane Chemical compound C1CC2CCN1NC2 QVCUKHQDEZNNOC-UHFFFAOYSA-N 0.000 description 1
- XOXUXLDFDIJSPF-UHFFFAOYSA-N 1-(bromomethyl)-2-methylcyclopropane Chemical compound CC1CC1CBr XOXUXLDFDIJSPF-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical group OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001135931 Anolis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 101100438134 Rattus norvegicus Cabs1 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- BCALRHVPKFQYMU-UHFFFAOYSA-N [Na].[Ru] Chemical compound [Na].[Ru] BCALRHVPKFQYMU-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- PXLAFWIVWICIRK-UHFFFAOYSA-N [difluoro(trifluoromethoxy)methyl] hypofluorite Chemical group FOC(F)(F)OC(F)(F)F PXLAFWIVWICIRK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- QDHFHIQKOVNCNC-UHFFFAOYSA-N butane-1-sulfonic acid Chemical class CCCCS(O)(=O)=O QDHFHIQKOVNCNC-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- NJOZRVFCNPTFKP-UHFFFAOYSA-N difluoromethyl hypofluorite Chemical group FOC(F)F NJOZRVFCNPTFKP-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- QKGYJVXSKCDGOK-UHFFFAOYSA-N hexane;propan-2-ol Chemical compound CC(C)O.CCCCCC QKGYJVXSKCDGOK-UHFFFAOYSA-N 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- AJKLKFPOECCSOO-UHFFFAOYSA-N hydrochloride;hydroiodide Chemical compound Cl.I AJKLKFPOECCSOO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- MUERZYSPGYLGBT-UHFFFAOYSA-N lithium;molecular hydrogen Chemical compound [Li].[H][H] MUERZYSPGYLGBT-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- OHZZTXYKLXZFSZ-UHFFFAOYSA-I manganese(3+) 5,10,15-tris(1-methylpyridin-1-ium-4-yl)-20-(1-methylpyridin-4-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 OHZZTXYKLXZFSZ-UHFFFAOYSA-I 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Definitions
- the present invention relates to an optically active pyrolipid pyridazine compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing an optically active pyrolipid pyridazine compound or a pharmaceutically acceptable salt thereof as an active ingredient (particularly ulcer)
- Optically active pyro-oral pyridazine compound for producing a pharmaceutical composition particularly, a composition for preventing or treating ulcerative disease or a pharmacologically acceptable salt thereof.
- diseases especially ulcer disease
- the present invention relates to a method or a method for producing an optically active pyrrolopyridazine compound or a pharmaceutically acceptable salt thereof.
- peptic ulcers are caused by an imbalance between the aggressive factors and protective factors on the gastric mucosa. Suppressing the secretion of gastric acid, which is an aggressive factor, is useful for the prevention and treatment of ulcers. is there.
- anticholinergic agents, histamine H2 receptor antagonists such as cimetidine, and proton pump inhibitors such as omebrazole have been widely used in clinical practice as effective drugs to suppress gastric acid secretion. ing.
- the above drugs have excellent ulcer treatment effects, recurrence of ulcers after discontinuation of use is a major problem.
- pyrrole-containing pyridazine derivatives are known as compounds having a gastric acid secretion inhibitory action and a gastric mucosa protective action (for example, W091 / 17164, W092 / 06979, W093 / 08190, etc.).
- a pyrrolic pyridazine derivative having an antibacterial activity against Helicobacter pylori is also known (for example, JP-A-7-247285).
- the present inventors strongly inhibited gastric acid secretion, which is an aggressive factor, protected gastric mucosa, and improved the antibacterial activity against Helicobacter pylori (Helicobacter pylori).
- a long-term research on the synthesis of piro-lipidazine derivatives and their pharmacological activities aimed at the development of anti-ulcer drugs with Pyridazine derivatives have a potent antimicrobial activity against Helicobacter pylori, as well as a potent gastric acid secretion inhibitory and mucosal protective effect.
- the present invention has been accomplished by providing an optically active pyro-opened pyridazine compound or a pharmacologically acceptable salt thereof, and an optically active pyro-opened pyridazine.
- Pharmaceutical compositions particularly compositions for the prevention or treatment of ulcerative diseases
- pharmaceutical compositions comprising a dazine compound or a pharmacologically acceptable salt thereof as an active ingredient.
- optically active pyro-ortho pyridazine compound or a pharmaceutically acceptable salt thereof for the production of a composition for therapy
- a process for preparing a pharmacologically acceptable salt is provided.
- the optically active pyro-opened pyridazine compound of the present invention is
- R 1 represents a C i -C 6 alkyl group
- R 2 and R 3 are the same or different and represent a C—Ce alkyl group
- R 4 is, C - C 6 ⁇ Bruno Kinore, Nono Rogeno C i-C 6 Anoreki / Les, CJ - in C 6 Anore Kokishi, substituents selected from the group consisting of halogeno C i-C 6 alkoxy and halogen-substituted May be C 6 —. Indicates an aryl group,
- A represents an imino group, an oxygen atom or a sulfur atom.
- it is a C 1 -C 4 alkyl group, more preferably Suitably, it is a methyl or ethyl group, most preferably a methyl group.
- the halogen atom contained in R 4 may be, for example, a fluorine, chlorine, bromine or iodine atom, preferably a fluorine, chlorine or bromine atom, and more preferably a fluorine or chlorine atom.
- the aryl group may be, for example, a phenyl or naphthyl group, preferably a fuunyl group.
- the number of substituents of the substituted aryl group is, for example, 1 to 5, preferably 1 to 3, more preferably 1 to 2, and particularly preferably 1 to 2. Individual.
- the aryl group is preferably phenyl, methylphenyl, trifluoromethylphenyl, methoxyphenyl, trifluoromethoxyphenyl, difluoromethoxyphenyl, phenololenophenyl, black phenyl, bu, Lomofeninole, diphnoleolofeninole, chlorofenolene Lofeninole, dichlorofeninole, trifenolene rofenenore, triclofenenore, naphtinole, methinolenaftinole, methoxynaphtinole, fluoronaphthyl, fluoronaphthyl Or bromonaphthinole group, and more preferably, feninole, 4-methinolephenine, 4 _trinoleolomethyiphenyl, 4-methoxyphenyole, 4 — trifluorometoxoxy
- A is preferably an oxygen or sulfur atom, and more preferably an oxygen atom.
- the pharmaceutically acceptable salts of compound (I) of the present invention are acid addition salts, for example, halogens such as hydrofluoride, hydrochloride, hydrobromide, hydroiodide Hydrochloride; Nitrate; Perchlorate; Sulfate; Phosphate; Carbonate; Methane snolefonate, Trifnorolelomethans tanolefonate, Etansnolefonate, Pentafluoroethanesnolefonate, Prono.
- halogens such as hydrofluoride, hydrochloride, hydrobromide, hydroiodide Hydrochloride
- Nitrate Perchlorate
- Sulfate Sulfate
- Phosphate Carbonate
- Methane snolefonate Trifnorolelomethans tanolefonate
- Etansnolefonate Pentafluoroethanesnolef
- C 6 alkyl sulfonate which may be substituted with fluorine atom, such as sulfonic acid salt, butanesulfonic acid salt, pentanosnoleic acid salt, hexansnolephonic acid salt; benzenesnolephonate, p-tonolenes C 6 — C-like like norephonate.
- fluorine atom such as sulfonic acid salt, butanesulfonic acid salt, pentanosnoleic acid salt, hexansnolephonic acid salt; benzenesnolephonate, p-tonolenes C 6 — C-like like norephonate.
- Aryl sulfonates such as acetate, propionate, butyrate, benzoate, fumarate, maleate, succinate, citrate, tartrate, oxalate, malonate Or an acid addition salt such as an amino acid salt such as glutamate or aspartate, and is preferably a hydrochloride, a sulfate or a carboxylate. It is the hydrochloride.
- the compound (I) of the present invention or a salt thereof can exist as a hydrate, and the present invention also includes those hydrates.
- R 4; ⁇ , one C 4 alkyl, Nono Rogeno C i-C 4 alkyl, Ji - C 4 alkoxy, halogeno C - C 4 alkoxy, fluorine, 1 to 3 is selected from the group consisting of chlorine and bromine Compounds which are fuunyl groups substituted with
- R 4 methyl, trifluormethino, methoxy, trifluorenomethoxy, difluoromethoxy, fluorine, chlorine and bromine substituted with one to three substituents selected from the group consisting of bromine A compound that is a group,
- R 4 is one or two substituents selected from the group consisting of fluorine and chlorine, and the substitution of one or two selected from the group consisting of the 2-, 4- and 6-positions is substituted.
- a compound that is a fuunyl group
- R 4 is a phenyl group substituted with 1 or 2 substituents selected from the group consisting of fluorine and chlorine and substituted at the 4-position or the 2,4-position.
- R JS a C i —C 4 alkyl group, R 2 and R 3 are the same or different and each is a C 4 -C 4 alkyl group; R 4 ; ⁇ , C—C 4 -alkyl, nodogeno C i -C 4 -alkyl, C — C 4 -alkoxy, halogeno ci-C 4 is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of C4 alkoxy, fluorine, chlorine and bromine, wherein A is an oxygen atom or a sulfur atom,
- R 1 is a methyl group
- R 4 is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of methyl, trifluoromethyl, methoxy, trifluoromethoxy, difluoromethoxy, fluorine, chlorine and bromine;
- R 1 is a methyl group
- R 4 is one or two substituents selected from the group consisting of fluorine and chlorine, and a phenyl group substituted with one or two substituents selected from the group consisting of 2-, 4- and 6-positions And
- R 1 is a methyl group
- R 4 is one or two substituents selected from the group consisting of fluorine and chlorine, and the 4- or 2,4-position is a substituted phenyl group; and A is oxygen A compound that is an atom.
- Illustrative compound number 1 4, 5, 7, 9, 10, 17, 18, 18, 21, 22, 24, 25, 31, 32, or 34, and still more preferably It is a compound of Exemplified Compound No. 4, 5, 9, 10, 21, 22, or 24, and particularly preferably, Compound No. 4: 7- (4-fluoropendinoleoxy) 1-2. , 3-Dimethyl-1- 1-[(1S, 2S) -2-Methylcyclopropylmethyl] pyro Mouth [2,3-d] pyridazine,
- the pyro-opened pyridazine derivative of the present invention can be easily produced by the method described below.
- R ⁇ R 2 , R 3 , R 4 and A have the same meanings as described above, R 5 represents a C 1-C 6 alkyl group, R 6 represents a hydrogen atom or a formyl group, X is a halogen atom (preferably a black atom, a promo or odo atom) or methanesulfonyloxy, ethansnolehoninoleoxy, butansnolehoninolexy, benzenesnolehoninoleoxy, tonoleensnolehoninole Oxy, naphthylene sulfoninoleoxy groups, etc. — C 6 phenol or C 6 — C ⁇ .
- the first step is a step of producing a compound having the general formula (IV), in which a compound having the general formula (II) and a compound having the general formula (III) are reacted in an inert solvent in the presence of a base.
- R 6 is a hydrogen atom, this can be achieved by further formylating the obtained compound.
- the base used in the reaction between compound (II) and compound (III) is, for example, lithium metal hydride such as lithium hydrogen hydride, sodium hydride, lithium hydride; lithium amide, sodium hydride.
- Alkali metal amides such as umamide and potassium amide; aluminum metal carbonates such as lithium carbonate, sodium carbonate and potassium carbonate; lithium methoxide, sodium methoxide, sodium ethoxide and potassium Al-metal alkoxides such as lithium t-butoxide; or triethylamine, tributylamine, disopropynoleethynoleamine, N-ethynolemonoleforin, pyridine, picolin , 4-(N, N-dimethylamino) pyridine, quinoline, N, N-dimethylenolanine, N, N-getinolealine, 1 , 5-diazabicyclo [4.
- Nona-1-diene (DBN), 1,4 diazabicyclo [2.2.2] octane (DABC0), 1, 8-diazabicyclo [5. 4. 0] It can be an organic amine, such as 7-ene (DBU), preferably an alkali metal hydride (especially sodium hydride) or an alkali metal alkoxide (especially, Potassium t-butoxide).
- DBU 7-ene
- alkali metal hydride especially sodium hydride
- an alkali metal alkoxide especially, Potassium t-butoxide
- the inert solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting materials to some extent.
- aliphatic hydrocarbons such as hexane, heptane, rig-in, and petroleum ether
- Aromatic hydrocarbons such as benzene, toluene and xylene
- methylene hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane, cyclobenzene, and dichlorobenzene
- getyl ether Disopropyl ether, tetrahydrofuran, dioxane, dimethoxetane, diethylene Ethers such as glycol dimethyl ether
- ketones such as acetone, methylethyl ketone, methyl isobutyl ketone, isophorone and cyclohexanone
- the reaction temperature is usually from 0 ° C to 250 ° C (preferably from room temperature to 150 ° C), and the time required for the reaction varies depending on the reaction temperature and the like, but is from 1 minute to 50 hours (preferably, 10 minutes to 30 hours).
- quaternary ammonium salts such as benzyltrimethylammonium chloride, tetrabutylammonium chloride, tetrabutylammonium bromide; or 18-crown-16 Crowns such as dibenzo-18-crown-18 can also be added.
- R 6 is a hydrogen atom
- the formylation of the compound obtained by the reaction between compound (II) and compound (III) is carried out in the presence or absence of an inert solvent by subjecting the corresponding compound to a Bielsmeier (Vismeier) Can be obtained by reacting with a reagent.
- the Vismeyer reagents used are known and include, for example, halogens such as phosphorous oxychloride-dimethylformamide, phosphorous oxybromide methylformamide, and oxalyl alkoxide red dimethylformamide.
- the agent is a dimethylformamide, preferably a phosphorous oxychloride-dimethylformamide.
- the inert solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting material to some extent.
- benzene, toluene, xy Aromatic hydrocarbons such as methylene chloride; halogenated hydrocarbons such as methylene chloride, chloroform-form, carbon tetrachloride, dichloroethane, cyclo-benzene, and dichlorobenzene; getyl ether, disopropyl ether Ethers such as tetrahydrofuran, dioxane, dimethoxetane, methylenglycol dimethyl ether; or amides such as dimethylformamide; preferably, halogenated hydrocarbons (particularly, Methylene chloride, chlorophonolem or dichloroethane).
- the reaction temperature is usually from ⁇ 20 ° C. to 150 ° C. (preferably from 0 ° C. to 100 ° C.).
- the time required for the reaction varies depending on the reaction temperature and the like, but is 15 minutes to 12 hours ( Preferably, it is 30 minutes to 5 hours.
- the second step is a step of producing a compound having the general formula (V), and is achieved by reacting the compound (IV) with hydrazine or a hydrate thereof in an inert solvent.
- the inert solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting materials to some extent.
- examples include getyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, and the like.
- good UNA Etenore such diethylene Gris co-one Norejimechinoree one Tenore; meta Nonore, Etano one Norre, Purono ⁇ 0 Nonore, Lee Sopurono ⁇ .
- Anoles such as phenols; aromatic hydrocarbons such as benzene, toluene and xylene; carboxylic acids such as acetic acid and propionic acid; formamide, dimethylformamide, dimethylacetamide, N-methyl-2- Amides such as pyrrolidone and hexamethyl phosphorotriamide; amines such as triethylamine and pyridin; water; or a mixed solvent thereof, preferably alcohols ( Particularly, it is ethanol) or carboxylic acids (especially, acetic acid).
- the reaction temperature is usually between -50 ° C and 150 ° C (preferably between 10 ° C and 120 ° C)
- the time required for the reaction varies depending on the reaction temperature and the like, but is 10 minutes to 12 hours (preferably 30 minutes to 5 hours).
- the third step is a step of producing a compound having the general formula (VI), and is achieved by reacting the compound (V) with a halogenating agent in the presence or absence of an inert solvent.
- the halogenating agent used can be, for example, phosphorus oxychloride, oxybromide, thionyl chloride, thionyl bromide, oxalyl chloride, pentachloride or pentabromide. It is phosphorus oxychloride or thionyl chloride, and can also be used in a large excess as a solvent.
- the inert solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting materials to some extent.
- aromatic hydrocarbons such as benzene, toluene and xylene; methylene chloride, and chlorine Halogenated hydrocarbons such as mouth form, carbon tetrachloride, dichloroethane, cyclobenzene, and dichlorobenzene; getyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxetane, diethylene glycol Ethers such as dimethinooleatenole; amides such as dimethinolehonolemamide, dimethylacetamide, N-methyl-2-pyrrolidone; or sulfoxides such as dimethylsulfoxide
- halogenated hydrocarbons particularly, methylene glycol In degrees or Axis Roroe Tan).
- the reaction temperature is usually 0 ° C. to 150 ° C. (preferably, room temperature to 120 ° C.).
- the time required for the reaction varies depending on the reaction temperature and the like, but is preferably 30 minutes to 12 hours (preferably, 1 hour to 6 hours).
- the fourth step is a step of producing the target compound (I), which is achieved by reacting the compound (VI) with a compound having the general formula (VII) in an inert solvent in the presence of a base.
- the step is performed in the same manner as in the first step.
- the target compound of each reaction is collected from the reaction mixture according to a conventional method. For example, if any insolubles are present, they are filtered off as appropriate and the solvent is distilled off, or after the solvent is distilled off, water is added to the residue and extracted with a suitable water-immiscible solvent. After drying over anhydrous magnesium sulfate or the like, the target compound can be separated by distilling off the solvent. If necessary, it can be purified by a conventional method, for example, by recrystallization, column chromatography or the like.
- Optical resolution of the corresponding racemic compound (one of the racemates corresponding to compound (1), (IV), (V) or (VI)) obtained by carrying out the same reaction using (Ilia)
- a desired optically active substance (IS, 2S-isomer)
- a usual method for example, a column chromatography method using an optical separation column, a preferential crystallization method, a method of resolving with diastereomer monosalt, or the like can be appropriately selected and performed. it can.
- compound U) is treated with an acid according to a conventional method to give a drug. It can be converted to a physiologically acceptable salt.
- inert solvents preferably ethers such as ether, tetrahydrofuran, dioxane; alcohols such as methanol, ethanol, propanol; or methylene chloride, chloroform, etc.
- Halogenated hydrocarbons are reacted with the corresponding acid at room temperature for 5 minutes to 1 hour, and the solvent is distilled off to obtain the desired salt.
- the starting compounds ( ⁇ ), (III) and (Ilia) are known or may be prepared by known methods (for example, JP-A-7-247285, Monatschefte fur CHemie (1973), 104,
- the compound having the general formula (I) or a pharmacologically acceptable salt thereof according to the present invention has an excellent inhibitory action on gastric acid secretion and a protective action on gastric mucosa, and an excellent antibacterial action on Helicobacter pylori.
- it is a drug, especially peptic ulcer, acute or chronic gastric ulcer, gastritis, reflux esophagitis, gastroesophageal reflex disease, dyspepsia, hyperacidity, Useful as a prophylactic or therapeutic agent (especially therapeutic agent) for ulcerative diseases such as Ringer-Ellison syndrome or a preventive or therapeutic agent (especially therapeutic agent) for Helicobacter pylori infection It is.
- the compound (I) of the present invention and a pharmacologically acceptable salt thereof are used as a medicament, particularly as an agent for preventing or treating the above-mentioned diseases
- the compound (I) itself or an appropriate pharmacologically acceptable salt is used.
- excipients e.g., lactose, sucrose, glucose, mannite, sugar derivatives such as sorbitol; corn starch, potato starch, c-starch, dextrin, carboxymethyl starch, etc.
- Such starch derivatives crystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropinolemethinoresenorelose, canoleboximethy / resenorelose, canoleboximethynoresenorelosecanolesum, internally crosslinked canolepoximethynorese
- Cellulose derivatives such as sodium ruthenium; arabia gum; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium metasilicate and magnesium phosphate; phosphates such as calcium phosphate Derivative; calcium carbonate
- a carbonate derivative such as calcium sulfate; a sulfate derivative such as calcium sulfate; a binder (eg, the above-mentioned excipient; gelatin; polybulpyrrolidone; magrogol); a disintegrant (eg, Excipients mentioned above; skull scalme, sodium, sodium carb
- an upper limit of 1000 mg preferably 500 mg
- a lower limit of 0.1 mg per day preferably lmg
- an upper limit of 500 mg (preferably , 300 mg) to an adult is preferably administered 1 to 6 times daily according to symptoms.
- reaction solution was poured into ice water and extracted with ethyl acetate.
- the extract was washed with brine and dried over anhydrous magnesium sulfate.
- hexane was added to the obtained concentrated liquid, and the precipitated crystals were collected by filtration to obtain crude crystals.
- the crude crystals were recrystallized from ethyl acetate / hexane to give 2.25 g (66.4%) of the title compound as pale brown crystals.
- the enzymatic reaction was started by adding 0.25 ml of 8 mM adenosine triphosphate 2 sodium salt solution. An enzymatic reaction was carried out for 20 minutes, and 1 ml of a 10% trichloro mouth acetic acid-activated carbon (100 mg ) solution was added. After centrifuging the reaction mixture (4 ° C, 3000 rpm, 15 minutes), the reaction mixture was purified by hydrolysis of adenosine triphosphate in the supernatant. The phosphoric acid was colorimetrically determined by the method of Yoda et al. [Biochem. Biophys. Res. Com, 40, 880 (1970)].
- the antimicrobial activity was evaluated by using Helicobacter pylori 9470, 9472 and 9474 strains, and the MIC (Minimum Inhib tory Concentration) of the compound of the present invention against Helicobacter pylori. J, growth inhibition concentration).
- Helicobacter pylori was cultured on a plate medium for 4 days.
- Brain Heart Infusion Agar manufactured by Difco
- poma blood manufactured by Biological Materials. What was dispensed and solidified so as to be used was used.
- a solution prepared by dissolving the compound of the present invention in dimethyl sulfoxide (DMSO) and serially diluting it with sterile distilled water at a ratio of 1:99 and the medium was solidified on a petri dish, and the mixture was solidified on a Petri dish to obtain a MIC measurement medium
- Helicobacter pylori was cultured under microaerobic conditions at 37 ° C for 3 days in the same manner as in the preculture. After completion of the culture, the growth of the fungus in the inoculated portion was visually observed. The small concentration was taken as MIC (/ ig / ml). As a result, the compound of Example 1 exhibited an excellent antibacterial activity of MIC of 12.5 ⁇ g / ml.
- the rats Four hours after the administration of the test compound or the suspension solvent, the rats were euthanized by inhaling carbon dioxide gas into the rats, and the abdomen was incised to remove the stomach.
- the contents of the stomach were collected in a centrifuge tube with a glass scale, centrifuged, and the volume of the supernatant (ml) and the volume of the sediment (ral) were measured. Those with a sediment volume of 0.5 ml or more were excluded from the data as feces.
- the supernatant 1001 was placed in a test tube, added with 4 ml of distilled water, and titrated to pH 7.0 with 0.01N sodium hydroxide.
- A Amount of sodium hydroxide (ml) required for titration of 100 ⁇ l of supernatant
- the powder of the above formulation is mixed and tableted with a tableting machine to make a tablet of 200 mg per tablet.
- the tablets can be sugar-coated or coated as needed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT00939072T ATE240957T1 (de) | 1999-06-15 | 2000-06-15 | Optisch aktive pyrrolopyridazin-derivate |
NZ516194A NZ516194A (en) | 1999-06-15 | 2000-06-15 | Optically active pyrrolopyridazine compounds |
AU54269/00A AU757611B2 (en) | 1999-06-15 | 2000-06-15 | Optically active pyrrolopyridazine compounds |
EP00939072A EP1186607B1 (en) | 1999-06-15 | 2000-06-15 | Optically active pyrrolopyridazine compounds |
BR0011666-1A BR0011666A (pt) | 1999-06-15 | 2000-06-15 | Derivado de pirrolpiridazina opticamente ativo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso em derivado de pirrolpiridazina opticamente ativo, método para tratar ou prevenir doença e, processo para sintetizar um derivado de pirrolpiridazina opticamente ativo ou um sal farmaceuticamente aceitável do mesmo |
DK00939072T DK1186607T3 (da) | 1999-06-15 | 2000-06-15 | Optisk aktive pyrrolopyridazinforbindelser |
DE60002860T DE60002860T2 (de) | 1999-06-15 | 2000-06-15 | Optisch aktive pyrrolopyridazin-derivate |
PL00356479A PL356479A1 (en) | 1999-06-15 | 2000-06-15 | Optically active pyrrolopyridazine compounds |
MXPA01013011A MXPA01013011A (es) | 1999-06-15 | 2000-06-15 | Compuestos de pirrolpiridazina opticamente activos. |
IL14708800A IL147088A0 (en) | 1999-06-15 | 2000-06-15 | Optically active pyrrolpyridazine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
CA002375848A CA2375848A1 (en) | 1999-06-15 | 2000-06-15 | Optically active pyrrolopyridazine compounds |
US10/021,214 US6670360B2 (en) | 1999-06-15 | 2001-12-12 | Optically active pyrrolopyridazine derivatives |
IL147088A IL147088A (en) | 1999-06-15 | 2001-12-13 | History 1 - (S1,2S) - 2, 3 - Dialkil - 7 - Transformed - 1H - Pyrrole - 2, 3 - d] Pyridicine with optical activity, pharmaceutical preparations containing them and methods for their preparation |
NO20016099A NO20016099L (no) | 1999-06-15 | 2001-12-14 | Optisk aktive pyrrolopyridazinforbindelser |
HK02105957.8A HK1044341B (zh) | 1999-06-15 | 2002-08-14 | 光學活性的吡咯並噠嗪化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/167679 | 1999-06-15 | ||
JP16767999 | 1999-06-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/021,214 Continuation US6670360B2 (en) | 1999-06-15 | 2001-12-12 | Optically active pyrrolopyridazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000077003A1 true WO2000077003A1 (fr) | 2000-12-21 |
Family
ID=15854223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/003895 WO2000077003A1 (fr) | 1999-06-15 | 2000-06-15 | Composes de pyrrolopyridazine optiquement actifs |
Country Status (25)
Country | Link |
---|---|
US (1) | US6670360B2 (ja) |
EP (1) | EP1186607B1 (ja) |
KR (1) | KR100583663B1 (ja) |
CN (1) | CN1170829C (ja) |
AT (1) | ATE240957T1 (ja) |
AU (1) | AU757611B2 (ja) |
BR (1) | BR0011666A (ja) |
CA (1) | CA2375848A1 (ja) |
CZ (1) | CZ290935B6 (ja) |
DE (1) | DE60002860T2 (ja) |
DK (1) | DK1186607T3 (ja) |
ES (1) | ES2198319T3 (ja) |
HK (1) | HK1044341B (ja) |
HU (1) | HUP0201434A3 (ja) |
IL (2) | IL147088A0 (ja) |
MX (1) | MXPA01013011A (ja) |
NO (1) | NO20016099L (ja) |
NZ (1) | NZ516194A (ja) |
PL (1) | PL356479A1 (ja) |
PT (1) | PT1186607E (ja) |
RU (1) | RU2222541C2 (ja) |
TR (1) | TR200103685T2 (ja) |
TW (1) | TWI287014B (ja) |
WO (1) | WO2000077003A1 (ja) |
ZA (1) | ZA200110279B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058901A1 (fr) * | 2000-02-10 | 2001-08-16 | Sankyo Company, Limited | Compose de pyrrolopyridazine |
WO2004029057A1 (ja) * | 2002-09-25 | 2004-04-08 | Sankyo Company, Limited | 内臓痛の治療または予防のための医薬組成物 |
WO2004029058A1 (ja) * | 2002-09-25 | 2004-04-08 | Sankyo Company, Limited | 血中ガストリン濃度上昇の抑制のための医薬組成物 |
EP1974730A1 (en) | 2003-11-03 | 2008-10-01 | AstraZeneca AB | Imidazo[1,2-a]pyridine derivatives for use in the treatment of sleep disturbance due to silent gastro-esophageal reflux |
WO2011004882A1 (ja) | 2009-07-09 | 2011-01-13 | ラクオリア創薬株式会社 | 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤 |
CN105367550A (zh) * | 2014-08-11 | 2016-03-02 | 江苏柯菲平医药股份有限公司 | 四氢环戊二烯并[c]吡咯类衍生物、其制备方法及其在医药上的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007002219A (es) * | 2004-09-03 | 2007-05-04 | Yuhan Corp | Derivados de pirrolo [3,2-b ] piridina y procesos para su preparacion. |
CN101003537A (zh) * | 2006-01-17 | 2007-07-25 | 上海恒瑞医药有限公司 | 吡咯并哒嗪类衍生物及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0742218A1 (en) * | 1994-01-19 | 1996-11-13 | Sankyo Company Limited | Pyrrolopyridazine derivative |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL97931A0 (en) | 1990-04-27 | 1992-06-21 | Byk Gulden Lomberg Chem Fab | Pyridazine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
WO1992006979A1 (de) | 1990-10-15 | 1992-04-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue diazine |
DK0609328T3 (da) | 1991-10-25 | 1999-10-25 | Byk Gulden Lomberg Chem Fab | Pyrrolo-pyridaziner med gastro-intestinal beskyttelsesvirkning |
-
2000
- 2000-06-13 TW TW089111505A patent/TWI287014B/zh not_active IP Right Cessation
- 2000-06-15 NZ NZ516194A patent/NZ516194A/xx unknown
- 2000-06-15 IL IL14708800A patent/IL147088A0/xx not_active IP Right Cessation
- 2000-06-15 TR TR2001/03685T patent/TR200103685T2/xx unknown
- 2000-06-15 DK DK00939072T patent/DK1186607T3/da active
- 2000-06-15 PL PL00356479A patent/PL356479A1/xx not_active Application Discontinuation
- 2000-06-15 AU AU54269/00A patent/AU757611B2/en not_active Ceased
- 2000-06-15 HU HU0201434A patent/HUP0201434A3/hu unknown
- 2000-06-15 MX MXPA01013011A patent/MXPA01013011A/es active IP Right Grant
- 2000-06-15 ES ES00939072T patent/ES2198319T3/es not_active Expired - Lifetime
- 2000-06-15 CN CNB008115990A patent/CN1170829C/zh not_active Expired - Fee Related
- 2000-06-15 RU RU2001134010/04A patent/RU2222541C2/ru not_active IP Right Cessation
- 2000-06-15 EP EP00939072A patent/EP1186607B1/en not_active Expired - Lifetime
- 2000-06-15 BR BR0011666-1A patent/BR0011666A/pt not_active IP Right Cessation
- 2000-06-15 CA CA002375848A patent/CA2375848A1/en not_active Abandoned
- 2000-06-15 WO PCT/JP2000/003895 patent/WO2000077003A1/ja active IP Right Grant
- 2000-06-15 AT AT00939072T patent/ATE240957T1/de not_active IP Right Cessation
- 2000-06-15 CZ CZ20014505A patent/CZ290935B6/cs not_active IP Right Cessation
- 2000-06-15 PT PT00939072T patent/PT1186607E/pt unknown
- 2000-06-15 KR KR1020017016061A patent/KR100583663B1/ko not_active IP Right Cessation
- 2000-06-15 DE DE60002860T patent/DE60002860T2/de not_active Expired - Fee Related
-
2001
- 2001-12-12 US US10/021,214 patent/US6670360B2/en not_active Expired - Fee Related
- 2001-12-13 IL IL147088A patent/IL147088A/en unknown
- 2001-12-13 ZA ZA200110279A patent/ZA200110279B/xx unknown
- 2001-12-14 NO NO20016099A patent/NO20016099L/no not_active Application Discontinuation
-
2002
- 2002-08-14 HK HK02105957.8A patent/HK1044341B/zh not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0742218A1 (en) * | 1994-01-19 | 1996-11-13 | Sankyo Company Limited | Pyrrolopyridazine derivative |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058901A1 (fr) * | 2000-02-10 | 2001-08-16 | Sankyo Company, Limited | Compose de pyrrolopyridazine |
US6734181B2 (en) | 2000-02-10 | 2004-05-11 | Sankyo Company, Limited | Pyrrolopyridazine compounds |
WO2004029057A1 (ja) * | 2002-09-25 | 2004-04-08 | Sankyo Company, Limited | 内臓痛の治療または予防のための医薬組成物 |
WO2004029058A1 (ja) * | 2002-09-25 | 2004-04-08 | Sankyo Company, Limited | 血中ガストリン濃度上昇の抑制のための医薬組成物 |
EP1974730A1 (en) | 2003-11-03 | 2008-10-01 | AstraZeneca AB | Imidazo[1,2-a]pyridine derivatives for use in the treatment of sleep disturbance due to silent gastro-esophageal reflux |
WO2011004882A1 (ja) | 2009-07-09 | 2011-01-13 | ラクオリア創薬株式会社 | 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤 |
JP5802898B2 (ja) | 2009-07-09 | 2015-11-04 | ラクオリア創薬株式会社 | 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤 |
CN105367550A (zh) * | 2014-08-11 | 2016-03-02 | 江苏柯菲平医药股份有限公司 | 四氢环戊二烯并[c]吡咯类衍生物、其制备方法及其在医药上的应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2136682C1 (ru) | Имидазопиридины, способ их получения, фармацевтическая композиция на их основе и способ получения фармацевтической композиции | |
JPH054983A (ja) | イソキノリノン誘導体、その製造方法およびその誘導体を有効成分として含有する5−ht3 レセプター拮抗剤 | |
EP0546181B1 (en) | Indole derivatives and their use as serotonin antagonists | |
WO2000077003A1 (fr) | Composes de pyrrolopyridazine optiquement actifs | |
US6734181B2 (en) | Pyrrolopyridazine compounds | |
US5990106A (en) | Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof | |
JP2003119140A (ja) | ピロロピリダジン化合物を含有する医薬 | |
JP3354132B2 (ja) | 光学活性なピロロピリダジン化合物 | |
JP3387066B2 (ja) | ピロロピリダジン化合物を含有する抗潰瘍剤 | |
JP2001294587A (ja) | ピロロピリダジン化合物 | |
JPS6270370A (ja) | キノロンカルボン酸誘導体およびその製造方法 | |
JPS59199693A (ja) | インドリルグリシルセフアロスポリン誘導体 | |
JP2621204B2 (ja) | 抗菌化合物 | |
FR2531084A1 (fr) | Nouveaux derives de la 7-(4-pyridyl)-1,8-naphtyridine, medicament et compositions pharmaceutiques en contenant | |
JP2951726B2 (ja) | ピリドンカルボン酸誘導体およびその合成中間体 | |
BE875469A (fr) | Nouveaux composes de type beta-lactame utiles comme agents antimicrobiens et leur procede de preparation | |
WO1996001260A1 (fr) | Derive d'acide pyridone-carboxylique, l'un de ses esters, l'un de ses sels, et produit intermediaire pour la synthese de ces composes | |
JPH01190687A (ja) | 抗菌化合物 | |
JPH04279586A (ja) | キサンチン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU ID IL IN KR MX NO NZ PL RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/1300/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000939072 Country of ref document: EP Ref document number: 10021214 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017016061 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2375848 Country of ref document: CA Ref document number: 2375848 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/013011 Country of ref document: MX Ref document number: PV2001-4505 Country of ref document: CZ Ref document number: 516194 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/03685 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 54269/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008115990 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000939072 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017016061 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-4505 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PV2001-4505 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000939072 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 54269/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017016061 Country of ref document: KR |